Cream with tapinarof alleviated the course of atopic dermatitis

The results of the ADORING 1 and ADORING 2 studies showed that tapinarof reduced the severity and area of lesions in patients with atopic dermatitis aged two years and older. Eight weeks after starting treatment, more than 45% of participants in the tapinarof group achieved clear or nearly clear skin.

Researchers from George Washington University confirmed the effectiveness of tapinarof cream in treating atopic dermatitis in adults and children aged two years and older at the annual congress of the European Academy of Dermatology and Venereology (EADV) in Berlin. The results of the ADORING 1 and ADORING 2 studies were published by Medscape.

At week 8 of treatment, more than 45% of participants using tapinarof cream achieved a "clear" (0 points) or "almost clear" (1 point) status on the vIGA scale. In the control group, only 14% of participants achieved this result. In addition, almost 60% of those who used the cream achieved 75% clearance (EASI75) on the EASI eczema severity and area scale. In the control group, only 24% of patients achieved a similar result.

The researchers noted a slight increase in the incidence of headache in the tapinarof group, but this was temporary. The frequency of treatment failure due to side effects was low in both groups.

The scientists emphasize: tapinarof cream can be used without restrictions on time, place or area of application, which distinguishes it from steroid creams.

A total of 813 people with moderate to severe atopic dermatitis participated in the ADORING 1 and ADORING 2 studies. Participants aged two years and older were randomly assigned into groups to apply tapinarof cream or placebo.

Experts emphasized that more than 90% of the participants continued to participate in the open-label ADORING 3 study with a planned follow-up of 48 weeks.